Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-Lung-1: obrixtamig + atezolizumab + carboplatin + etoposide vs atezolizumab + carboplatin + etoposide in first-line ES-SCLC
jRCT2071250151Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of obrixtamig in small cell lung cancer (SCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Overall survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2071250151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250151.